

Kristin M D'silva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1614731/publications.pdf>

Version: 2024-02-01

32
papers

2,127
citations

686830

13
h-index

454577

30
g-index

35
all docs

35
docs citations

35
times ranked

4863
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2333-2344.	13.9	1,102
2	Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US "hot spot". <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1156-1162.	0.5	217
3	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.5	151
4	COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 914-920.	2.9	117
5	Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 660-666.	0.5	74
6	Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 289-291.	0.5	69
7	Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. <i>Arthritis and Rheumatology</i> , 2021, 73, 374-380.	2.9	66
8	SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 817-819.	0.5	37
9	DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152025.	1.6	36
10	COVID-19 and rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2021, 33, 255-261.	2.0	32
11	Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e638-e647.	2.2	30
12	Coronavirus Disease 2019 Outcomes Among Recipients of Anti-CD20 Monoclonal Antibodies for Immune-Mediated Diseases: A Comparative Cohort Study. <i>ACR Open Rheumatology</i> , 2022, 4, 238-246.	0.9	27
13	Increased Risk of COVID-19 in Patients With Rheumatoid Arthritis: A General Population-Based Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 741-747.	1.5	19
14	Incident systemic rheumatic disease following COVID-19. <i>Lancet Rheumatology, The</i> , 2021, 3, e402-e404.	2.2	17
15	Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score-Matched Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 52-60.	3.1	15
16	COVID-19 and Disease-Modifying Anti-rheumatic Drugs. <i>Current Rheumatology Reports</i> , 2021, 23, 28.	2.1	15
17	Hypouricemia and Mortality Risk in the US General Population. <i>Arthritis Care and Research</i> , 2021, 73, 1171-1179.	1.5	14
18	Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series. <i>Clinical Lung Cancer</i> , 2021, 22, e738-e744.	1.1	14

#	ARTICLE	IF	CITATIONS
19	Persistent premature mortality gap in dermatomyositis and polymyositis: a United Kingdom general population-based cohort study. <i>Rheumatology</i> , 2020, 60, 2653-2660.	0.9	8
20	Using electronic visits (E-visits) to achieve goal serum urate levels in patients with gout in a rheumatology practice: A pilot study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1382-1386.	1.6	8
21	Response to: "Correspondence on SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease" by C et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e131-e131.	0.5	8
22	Assessing the Severity of COVID-19 Lung Injury in Rheumatic Diseases Versus the General Population Using Deep Learning-Derived Chest Radiograph Scores. <i>Arthritis Care and Research</i> , 2023, 75, 657-666.	1.5	8
23	Mortality trends in polymyositis and dermatomyositis: A general population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 834-839.	1.6	7
24	Rituximab for interstitial pneumonia with autoimmune features at two medical centres. <i>Rheumatology Advances in Practice</i> , 2021, 5, ii1-ii9.	0.3	7
25	Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020. <i>Journal of General Internal Medicine</i> , 2022, 37, 1917-1924.	1.3	5
26	Response to: "COVID-19 in patients with rheumatological diseases treated with Anti-TNF" by Brito et al and "Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China: a hot spot versus in US hot spot: similarities and differences" by Zhao et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e64-e64.	0.5	4
27	Response to: "COVID-19 in patients with rheumatic diseases: what is the real mortality risk?" by Marques et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e135-e135.	0.5	3
28	Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 708-711.	1.0	3
29	Gender Differences in the Amount and Type of Student Participation During In-Person and Virtual Classes in Academic Medicine Learning Environments. <i>JAMA Network Open</i> , 2022, 5, e2143139.	2.8	3
30	Response to: "Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors" by Jovani et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e132-e132.	0.5	1
31	Temporal Trends in Prescribing of Bone-Directed Therapies in the United States, 2009-2020. <i>Journal of the Endocrine Society</i> , 2021, 5, A250-A250.	0.1	1
32	Transient blindness with periorbital erythema and swelling: Manifestations of recurrent systemic lupus erythematosus. <i>JAAD Case Reports</i> , 2019, 5, 1088-1090.	0.4	0